SANTA CLARA, California, June 25, 2024 /PRNewswire/ — Zeto, Inc., an award-winning medical technology company, is proud to announce the winners of its 2024 Clinical Trial Sponsorship program. This initiative, announced at the 2023 Society for Neuroscience Convention in Washington DC, invited research teams to submit proposals for clinical trials using the Zeto EEG device platform. The program aims to support advanced clinical research and bring innovative applications closer to real-world implementation.
Zeto announces winners of 2024 Clinical Trial Sponsorship Program.
An expert jury panelcomposed of professionals from the fields of neurology and neuroscience research, carefully reviewed all entries and selected the winners based on various factors, including alignment with Zeto’s mission to improve patient care through innovative EEG applications.
“The winners of the 2024 Clinical Trial Sponsorship program are conducting groundbreaking research aimed at improving patient care. These projects fit perfectly with Zeto’s mission, and we are proud to support them. We look forward to the annual to continue with this sponsorship program,” said Florian Strelzyk, Chief Sales Officer at Zeto.
The winners of the 2024 Clinical Trial Sponsorship program are:
- Effectiveness of Portable EEG Technology in Pre-Hospital Triage of Large Vessel Occlusion Strokes because of Liqi ShuM.D and a multidisciplinary team Brown University and Rhode Island Hospital, USA
This clinical trial will evaluate the ability of the Zeto EEG system to improve pre-hospital triage of large vessel occlusion (LVO) strokes, with the aim of significantly improving diagnostic speed and accuracy. By integrating Zeto’s advanced, portable EEG technology into EMS protocols, the study seeks to ensure rapid and appropriate routing of stroke patients to specialized care facilities, thereby optimizing treatment times and patient outcomes.
Brain-computer interfaces (BCIs) have served paralyzed individuals by directly decoding their brain activity. A popular paradigm requires the patient to look at displayed targets, but this is challenging for patients with limited to no eye control. Prof. Hulle’s team has developed a gaze-independent paradigm and EEG decoder that deals with this problem, which will be tested on patients with the Zeto EEG headset.
- The Far-North Remote Online Zeto Electroencephalography (FROZE) Trial because of Marcus C. Ng, MD of University of ManitobaCanada
The FROZE Trial will use Zeto EEG in an emergency room in the far north of the Canadian Arctic for use by everyday clinicians supported by remote interpretation by board-certified epileptologists. This trial will determine how effectively the Zeto platform could improve patient care in even the most remote regions of the earth.
“We are happy to support the winners of the Clinical Trial Sponsorship program and to see the benefits of Zeto’s dry EEG headset in action. important benefits for researchers in projects like this,” said A. Mark MentoDirector of Enterprise Sales at Zeto.
Zeto will supply each clinical trial with its FDA-approved products, including up to two headsets per trial along with electrodes for up to 100 patients, accompanied by on-site training and ongoing product support. Trials are set to begin before the end of 2024 with an expected duration ranging between 6 to 12 months.
Information about the company Zeto, Inc.
Zeto, Inc., an award-winning medical technology company, is at the forefront of advancing EEG brain monitoring and diagnostics for healthcare.
Zeto’s revolutionary FDA-cleared EEG platform brings the traditional EEG procedure into the 21st century by offering a zero-prep, wireless, easy-to-wear, wearable headset with active, dry electrodes that can be placed either in front of the 10 -20 system.
The company plans to leverage its platform technology to improve access and quality for medical EEG testing and to enable and improve adjacent biomedical research and clinical trials.
To learn more about Zeto’s products, please visit https://zeto-inc.com or email us (email protected).
SOURCE Zeto, Inc.